Novo
Novo Nordisk is a global leader in diabetes care and chronic disease treatment, headquartered in Denmark, with a century-long legacy of pharmaceutical innovation and worldwide impact.
Novo Nordisk is a global leader in diabetes care and chronic disease treatment, headquartered in Denmark, with a century-long legacy of pharmaceutical innovation and worldwide impact.
Import Shipments
Distribution Centers
Annual Revenue
Founded
Novo Nordisk is likely advancing its leadership in diabetes and obesity care through new drug launches, digital health solutions, and expanded global access initiatives.
Launch of next-generation GLP-1 therapies for diabetes and obesity
Strategic efforts to expand market presence and reach new customer segments.
Implementation of advanced technologies to improve service delivery and customer experience.
Novo Nordisk develops and manufactures innovative medicines for chronic diseases, with a primary focus on diabetes care, obesity management, and rare endocrine disorders. The company’s product portfolio includes insulin, GLP-1 receptor agonists, and other advanced therapies that have transformed patient outcomes globally. Novo Nordisk operates extensive research, production, and distribution networks, ensuring its products reach patients in more than 170 countries. The company is committed to driving change in healthcare through scientific excellence, sustainability, and patient-centered solutions.
